All Updates

All Updates

icon
Filter
Funding
OpGen announces a USD 3.5 million public offering
Precision Medicine
May 1, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

May 1, 2023

OpGen announces a USD 3.5 million public offering

Funding

  • Molecular diagnostics and bioinformatics company OpGen announced a public offering of 4.5 million shares and warrants. The company expects to raise gross proceeds of USD 3.5 million at a price of USD 0.7785 per share. The offering window is expected to close on or about May 04, 2023.

  • OpGen plans to use proceeds from the offering for various purposes, including supporting the commercialization of its Acuitas AMR Gene Panel test, commercializing products on the Unyvero Platform, and investing in research and development.

  • OpGen develops and commercializes molecular diagnostics and bioinformatics solutions to combat infectious diseases, together with its subsidiaries, Curetis GmbH and Ares Genetics GmbH. OpGen's product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform, which incorporates advanced technologies such as next-generation sequencing and AI-powered bioinformatics for antibiotic response prediction. It also offers the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.